```html

Zollinger‑Ellison Gastric Hypersecretion

Overview

Zollinger‑Ellison syndrome (ZES) is a rare endocrine disorder in which one or more gastrin‑producing tumors (gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to produce very large amounts of gastric acid—a condition known as **gastric hypersecretion**. This acidic environment can cause severe peptic ulcers, diarrhea, and malabsorption.

Who it affects: ZES can occur at any age but is most commonly diagnosed in adults between 30 and 60 years. Both men and women are affected almost equally.

Prevalence: Gastrinomas are estimated to occur in about 1 – 3 per million people per year. Approximately 20‑30 % of patients with gastrinomas have multiple endocrine neoplasia type 1 (MEN‑1), an inherited disorder that predisposes to tumors of the parathyroid, pituitary, and pancreas.

Sources: Mayo Clinic, Mayo Clinic; NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Symptoms

Because the hallmark of ZES is excessive gastric acid, symptoms are mainly related to ulcer disease and acid‑induced injury to the gastrointestinal (GI) tract. The presentation can be variable, ranging from mild dyspepsia to life‑threatening bleeding.

Typical symptom profile

• Refractory peptic ulcers – ulcers that persist despite standard therapy, often located in unusual sites such as the jejunum, distal duodenum, or even the ileum.
• Abdominal pain – burning or gnawing pain that may improve with meals (due to buffering) but often recurs later.
• Heartburn / gastro‑esophageal reflux disease (GERD) – chronic acid exposure to the esophagus.
• Diarrhea – watery, sometimes fatty (steatorrhea) due to acid inactivation of pancreatic enzymes and bile salts.
• Nausea and vomiting – especially after large meals.
• Weight loss – secondary to malabsorption and reduced oral intake.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Perforation – a surgical emergency when an ulcer creates a hole in the gut wall.
• Mortality‑related signs – unexplained anemia, chronic fatigue, or severe electrolyte disturbances from prolonged diarrhea.

Less common / associated symptoms

• Fatigue due to iron‑deficiency anemia from chronic bleeding.
• Hypocalcemia if associated with MEN‑1‑related hyperparathyroidism.
• Neurologic signs (headache, confusion) from metabolic imbalances.

Causes and Risk Factors

Primary cause

The underlying cause is a gastrin‑secreting neuroendocrine tumor (gastrinoma). Approximately 70 % are sporadic, while 25‑30 % occur in the setting of MEN‑1. Tumors are usually <1 cm in size but can be multiple and sometimes malignant (up to 25 % develop metastases, most often to the liver or regional lymph nodes).

Risk factors

• Genetic predisposition – a family history of MEN‑1 (mutation in the MEN1 gene) markedly increases risk.
• Previous pancreatic or duodenal neuroendocrine tumors – patients with other neuroendocrine neoplasms have a higher chance of developing gastrinomas.
• Chronic atrophic gastritis – can cause secondary hypergastrinemia, but does not lead to true ZES; however, it may mask early symptoms.
• Age and sex – no strong demographic predilection, though diagnosis is slightly more frequent in men.
• Environmental factors – no clear link, but smoking may worsen ulcer disease.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is required, especially when ulcers are refractory or located distal to the duodenum.

Step‑wise diagnostic approach

1. Fasting serum gastrin level – measured after an overnight fast. Levels > 1,000 pg/mL are highly suggestive of ZES, but values > 150 pg/mL with a positive secretin stimulation test are diagnostic.
2. Secretin stimulation test – paradoxical rise in gastrin after IV secretin administration (≥ 120 pg/mL increase) confirms gastrin‑independent hypersecretion.
3. Upper endoscopy (EGD) – visualizes ulcer location, number, and severity. Biopsies are taken to exclude H. pylori infection or malignancy.
4. Imaging for tumor localization:
   • Multiphasic contrast CT or MRI of the abdomen.
   • Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT, which have > 90 % sensitivity for small gastrinomas.
   • EUS (endoscopic ultrasound) for lesions < 1 cm in the pancreas or duodenum.
5. Assessment for MEN‑1 – serum calcium, PTH, prolactin and pituitary MRI if clinical suspicion exists.

Reference: Cleveland Clinic, Zollinger‑Ellison Syndrome.

Treatment Options

Therapy aims to (1) control acid hypersecretion, (2) eradicate or reduce tumor burden, and (3) monitor for recurrence or metastasis.

Acid‑suppression medications

• High‑dose Proton Pump Inhibitors (PPIs) – e.g., omeprazole 60‑120 mg/day, esomeprazole 40‑80 mg/day, or pantoprazole 80‑120 mg/day. PPIs are the mainstay; > 90 % of patients achieve ulcer healing within 4–6 weeks.
• H2‑receptor antagonists – less effective alone but can be used as adjunct therapy in patients with PPI intolerance.

Surgical management

• Enucleation or pancreaticoduodenectomy – indicated when the tumor is localized and resectable, especially for solitary gastrinomas < 2 cm without metastasis.
• Debulking surgery – may improve symptoms in patients with metastatic disease.
• Liver-directed therapies (e.g., radiofrequency ablation) for hepatic metastases.

Medical therapies for tumor control

• Somatostatin analogues – octreotide or lanreotide can lower gastrin secretion and may shrink tumor size.
• Targeted therapy – everolimus (mTOR inhibitor) has shown benefit in progressive neuroendocrine tumors.
• Chemotherapy – reserved for high‑grade or rapidly progressive disease; regimens often include streptozocin combined with 5‑FU or doxorubicin.
• Peptide receptor radionuclide therapy (PRRT) – 177Lu‑DOTATATE for somatostatin‑receptor positive metastases; improves progression‑free survival (NETTER‑1 trial).

Lifestyle & supportive measures

• Avoid NSAIDs, aspirin, and other ulcerogenic drugs.
• Limit alcohol and smoking.
• Eat small, frequent meals; avoid large fatty meals that can trigger acid spikes.

Living with Zollinger‑Ellison Gastric Hypersecretion

Daily management tips

• Medication adherence – take PPIs exactly as prescribed (usually 30 minutes before breakfast). Carry a spare prescription in case of travel.
• Monitoring symptoms – keep a brief diary of pain, stool frequency, and any bleeding episodes; share with your gastroenterologist every 3–6 months.
• Nutritional considerations – supplement iron, calcium, and vitamin B12 if malabsorption is present; a dietitian can tailor a low‑acid, high‑protein plan.
• Regular follow‑up imaging – typically every 6–12 months to assess tumor status.
• Vaccinations – if you undergo splenectomy or receive systemic therapy, stay up‑to‑date on pneumococcal, influenza, and COVID‑19 vaccines.

Psychosocial aspects

Chronic disease can be stressful. Consider support groups (e.g., FDA‑approved Rare Disease Patient Advocacy Groups) and counseling. Online platforms such as the Zollinger‑Ellison Syndrome Association provide resources and peer connections.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk can be reduced through the following measures:

• Family screening for MEN‑1: first‑degree relatives of a confirmed MEN‑1 case should undergo genetic counseling and periodic biochemical testing.
• Eradicate Helicobacter pylori infection when present – while it does not cause ZES, it can exacerbate ulcer disease.
• Avoid chronic use of ulcer‑inducing medications (NSAIDs, high‑dose steroids) unless medically necessary.
• Maintain a healthy lifestyle (balanced diet, no smoking, limited alcohol) to lower overall gastrointestinal stress.

Complications

If left untreated or poorly controlled, gastric hypersecretion associated with ZES can lead to serious, sometimes life‑threatening complications:

• Recurrent or perforated peptic ulcers – risk of peritonitis and sepsis.
• Upper gastrointestinal bleeding – may require endoscopic hemostasis or surgery.
• Gastric outlet obstruction – from scarring or ulcer-induced edema.
• Malabsorption & nutritional deficiencies – chronic diarrhea can cause hypokalemia, hypocalcemia, and fat‑soluble vitamin deficiencies.
• Metastatic gastrinoma – liver or lymph‑node spread reduces survival; median 5‑year survival drops from > 90 % (localized disease) to ~ 50 % (metastatic).
• Secondary gastric carcinoids – prolonged hypergastrinemia can stimulate enterochromaffin‑like (ECL) cell hyperplasia.

When to Seek Emergency Care

---

© 2026 HealthGuide Content. All information provided is for educational purposes and does not replace professional medical advice. Consult your physician for personalized diagnosis and treatment.

```